Member Info for bots

Come on Zen, sort it with customs and let’s get show on road.

Well you can’t say they’re not getting on with it.
Meanwhile I like the saucer shaped chart being formed. If only I had more funds to buy.

Time for a tree shake.

I’m waiting! ??

Looking at the C-37 rig on the C-30 Twitter photo it seems the Top Drive guides are in place ready to go. One of the oilies on this BB might like to confirm.

Any thoughts on what this could be?
Perhaps a couple of speculative positives and negatives? ??

When I said shake I meant SHAKE.??
I expecting -20%.
MMS will need the shares to sell. Meanwhile punters will be thinking the top drive has fallen off a cliff.
But WTFDIK

It may not be next week. Will happen when it happens, but I would be concerned if it’s longer than this month. Before the rise of course there’s going to be a tree shake. Greedy mms will need some cheep shares to flog back to the weak holders. We’ll know things are about to happen after this I guess. I have a small wedge in reserve to do a little mopping.

Sorry but I don’t get how buying a rig for extra shares is dilution of shareholder value. If the board had bought consumable items or used a placing to pay wages or debt then yes, dilution. But a rig that can be used over and over and reduces cash burn on rental fees is an asset on the balance sheet; an expansion of the company. I happen to think a canny move, ‘coz rental rigs can be in demand and thus unavailable when we need them. We could also loan ours out if not needed. Correct me if I'm wrong.

Brave to mention your losses Kelbells. My style of investment is total risk and I've been hammered myself far too many times. But investing for years for a 4% return is boring. As long as the dosh is disposable, losses can't hurt too much but the wins could be transformative.
Just need some luck.

"Not expected to take long" suggests less than a week IMO.
Any longer than a week and investors are going to be shouting "are we there yet?"
Here we are analysing every crumb of info and yet when an RNS arrives I bet many punters will scarcely give it a glance.

BTW, the lorry transporting the top drive has the logo ABC (similar truks shown in earlier video with logo visible). I doubt that helps us identifying location although the transport company is registered in Turkey.
https://cargoagent.net/company%20profile/Transport_company/Turkey/Kayseri/ABC_ULUSLARASI_TRANSPORT_TIC__ve_SAN__A_S(i_230602279).html

Having exhausted other methods of ID, I also resorted to a thorough review of the landscape. I’ve concluded that it was taken from the A417 just outside Malvern. ??

Last time I encountered directors buying tons of shares and handing them on to family members was Caladon Resources. I had quite a large holding there and when I sold, I was able to pay off my mortgage!
I'm still accumulating here so will be glad of an extra chance to top up.

On conspiracy theories, since I don't know the company that well, may I ask:-
When did AC start buying agressively? Does this coincide with some particular event or RNS?

Cheers
Bots

All you have to do is say something like BOOM!! Ooops

I sold out of IMM last week and bought here. At least MTFB have a future and yet very undervalued. A good substitute for IMM but with and end point P3 study. Hopefully there’ll be no more dilution. Would prefer a partnership.

Remember, Lupuzor could get a fast track Conditional Marketing Authorisation within weeks. It would send the SP north of where we were before the collapse. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000925.jsp&mid=WC0b01ac05809f843b

The arguement that the drug 'won't' be approved is obviously incorrect. Instead Lupuzor could be approved and seems to fulful the requirements for a conditional marketing authorisation (EMA). There are other approval classes ------------------------ "The European Medicines Agency (EMA) supports the development of medicines that address unmet medical needs of patients. In the interest of public health, applicants may be granted a conditional marketing authorisation for such medicines where the benefit of immediate availability outweighs the risk of less comprehensive data than normally required, based on the scope and criteria defined in legislation and guidelines." 1/ Lupuzor is effecacious (no doubt). 2/ Lupuzor has no side effects (no doubt). 3/ There is an unmet medical need (no doubt). Accelerated authorisation: "For products deemed suitable for a conditional marketing authorisation, applicants are also encouraged to consider requesting accelerated assessment... Evaluating a marketing-authorisation application under the centralised procedure can take up to 210 days, not counting clock stops when applicants have to provide additional information. On request, the CHMP can reduce the timeframe to 150 days if the applicant provides sufficient justification for an accelerated assessment." http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000955.jsp&mid=WC0b01ac05809f843a So possible conditional marketing authorisation (EMA) by September; maybe the German article was right. And yet several 'know it alls' on this site have said that authorisation would be impossible by the end of the year. Wrong! ----------------------------- I'm sure the FDA will have a similar authorisation criteria. To say that noone would buy Lupuzor is also incorrect. People spend a fortune on all sorts of medicines, some with no research on them at all. So rubbish.

I think that IMM will do a close analysis of the data before applying for conditional marketing authorisation. There may be dosing issues, route issues or patient targetting issues; which P3 data will help resolve. From the EMA website; Lupuzor ticks the relevant boxes IMV 1/ "aimed at treating, preventing or diagnosing seriously debilitating or life-threatening diseases;" - Lupus [tick] 2/ "the benefit-risk balance of the product is positive"; - Lupuzor is efficacious and has zero side effects, [tick]. 3/ "It is likely that the applicant will be able to provide comprehensive data"; IMM have data for phases 1-3 [tick]. 4/ "unmet medical needs will be fulfilled;" Very few medications for Lupus, most have severe side effects with long-term use e.g. steroids [tick]. 5/ "the benefit to public health of the medicinal product's immediate availability on the market outweighs the risks due to need for further data." Again, Lupuzor is efficacious and has zero side effects, [tick]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000925.jsp&mid=WC0b01ac05809f843b Interestingly, these are the very issues highlighted by the company. IMM are a very small pharma and, as many have pointed out, have done well to get this far with limited resources. The EMA conditional marketing authorisation has been developed partly with this type of situation in mind. Although a CMA would allow IMM to market and profit from Lupuzor, there are obligations attached to this authorisation. "The holder will be required to complete specific obligations (ongoing or new studies, and in some cases additional activities) with a view to providing comprehensive data confirming that the benefit-risk balance is positive." "Once comprehensive data on the product have been obtained, the marketing authorisation may be converted into a standard marketing authorisation (not subject to specific obligations). Initially, this is valid for 5 years, but can be renewed for unlimited validity." The benefit would be that they will have a funding stream to conduct ongoing studies which are likely to be better targetted. There pre-authorisation guidance here: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/q_and_a/q_and_a_detail_000167.jsp&mid=WC0b01ac0580b18196 In conclusion, the results were mixed and would probably have benefited from a lager study (which is outside the scope of IMM ability currently). As such I imagine the p3 study is being used like a comprehensive p2b study which will help the company with further testing. We all have our time scales. I'm a long-term buy and hold and will simply ride out the short-termer games. As milestones are achived I'll buy more. Hopefully you'll agree with me that my comments above are objective and factual.

Lupuzor will gain conditional marketing authorisation based on the criteria below IMO: Yes the SP is a nightmare, but there's simply no reason to sell and every reason to hold. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000925.jsp&mid=WC0b01ac05809f843b

Nolupus I don't shoot the messenger I just think you don't know what you're talking about. In fact I know you don't know what you're talking about. So ignore. But what does get my back up is if you end up cheating folk out of their investments with rubbish information just so you can make money on your short position. Now that stinks.

Saying Lupuzor is a bust just because of the non-significance in the trial is shortsighted and wrong - see paper below. Fortunately regulatory bodies are full of people who understand this rather than a bunch of know-nothings. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4571159/ "Trials that claim superiority of an intervention most often try to reject the null hypothesis, which generally states that the effect of an intervention of interest is no different from the control. In this editorial, we introduce a conceptual framework for readers, reviewers, and those involved in guideline development. This paradigm is based on evaluating a study on its statistical merits (result-based merit) as well as the clinical relevance of the potential treatment effect (process-based merit)." "What should be clear is that a large P value does not in any way prove that H0 is true. When H0 is not rejected, it implies that either H0 is actually true, reflecting a correct decision (lower left cell of Table 1), or that H0 is actually false but that there was not enough evidence observed to reject H0, a type II error (lower right cell of Table 1). When H0 is rejected, it implies that either H0 is actually false, reflecting a correct decision (upper right cell of Table 1), or that H0 is actually true, but the evidence observed is �unlikely� (which will occur with probability α when the null hypothesis is true; upper left cell of Table 1)."